Stock Price
86.56
Daily Change
-1.76 -1.99%
Monthly
21.90%
Yearly
-1.16%
Q4 Forecast
85.56

EPS Reference Time Actual Consensus Previous
2026-10-30 FY2026Q3 3.55 3.06 2.91
2026-07-30 FY2026Q2 2.09 1.92 1.59
2026-04-23 FY2026Q1 1.88 1.8 1.38
2026-01-29 FY2025Q4 1.53 1.41 1.31
2025-10-24 FY2025Q3 2.91 2.84 2.86



Peers Price Chg Day Year Date
AbbVie 292.82 -1.73 -0.59% 25.21% Nov/17
Aena 28.40 -0.78 -2.67% 26.56% Nov/17
Alcon AG 61.80 -0.34 -0.55% 3.10% Nov/17
Almirall 10.50 -0.14 -1.32% -14.63% Nov/17
Amgen 457.93 -4.39 -0.95% 33.12% Nov/17
Amarin 11.22 -0.10 -0.84% -32.88% Nov/17
AstraZeneca 13,802.00 -232.00 -1.65% 1.74% Nov/17
Bayer 56.14 -0.86 -1.51% 105.12% Nov/17
Biogen 250.79 -0.86 -0.34% 48.55% Nov/17
BMW 56.10 -0.88 -1.54% -33.73% Nov/17

Indexes Price Day Year Date
EU50 6219 -129.55 -2.04% 12.36% Nov/17
FR40 8217 -135.22 -1.62% 3.12% Nov/17
EU100 1876 -34.94 -1.83% 11.66% Nov/17
EU600 651 -11.59 -1.75% 15.82% Nov/17

Sanofi traded at 86.56 this Tuesday November 17th, decreasing 1.76 or 1.99 percent since the previous trading session. Looking back, over the last four weeks, Sanofi lost 21.90 percent. Over the last 12 months, its price fell by 1.16 percent. Looking ahead, we forecast Sanofi to be priced at 85.56 by the end of this quarter and at 79.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.



News Stream
Sanofi Shares Hit 51-week High
Sanofi shares increased to 87.62 EUR, the highest since November 2025. Over the past 4 weeks, Sanofi gained 22.37%, and in the last 12 months, it decreased 2.78%.
2026-11-12
Sanofi Shares Hit 5-week High
Sanofi shares increased to 75.31 EUR, the highest since September 2026. Over the past 4 weeks, Sanofi gained 4.59%, and in the last 12 months, it decreased 13.69%.
2026-10-27
Sanofi Stock Price Hits 6-1/2-year Low
Sanofi shares decreased to 70.94 EUR, the lowest since March 2020. Over the past 4 weeks, Sanofi lost 7.59%, and in the last 12 months, it decreased 16.16%.
2026-10-02